Literature DB >> 17403870

Filamentous influenza A virus infection predisposes mice to fatal septicemia following superinfection with Streptococcus pneumoniae serotype 3.

Janice L Speshock1, Nicole Doyon-Reale, R Rabah, Melody N Neely, Paul C Roberts.   

Abstract

Previous studies have demonstrated that animals exposed to Streptococcus pneumoniae while recovering from influenza A virus infection exhibit exacerbated disease symptoms. However, many of the current animal models exploring dual viral and bacterial synergistic exacerbations of respiratory disease have utilized mouse-adapted influenza virus and strains of Streptococcus pneumoniae that in themselves are highly lethal to mice. Here we describe a mouse model of bacterial superinfection in which a mild, self-limiting influenza virus infection is followed by mild, self-limiting superinfection with S. pneumoniae serotype 3. S. pneumoniae superinfection results in rapid dissemination of the bacterium from the respiratory tract and systemic spread to all major organs of the mice, resulting in fatal septicemia. This phenomenon in mice was observed in superinfected animals undergoing an active viral infection as well as in mice that had completely cleared the virus 7 to 8 days prior to superinfection. Neutrophils were the predominant cellular inflammatory infiltrate in the lungs of superinfected mice compared to singly infected animals. Among other cytokines and chemokines, the neutrophil activator granulocyte colony-stimulating factor (G-CSF) was found to be significantly overexpressed in the spleens, lungs, and brains of superinfected animals. High G-CSF protein levels were observed in sera and lung lavage fluid from superinfected animals, suggesting that G-CSF is a major contributor to synergistic exacerbation of disease leading to fatal septicemia.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17403870      PMCID: PMC1932876          DOI: 10.1128/IAI.01943-06

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  36 in total

1.  Neutralization of macrophage inflammatory protein 2 (MIP-2) and MIP-1alpha attenuates neutrophil recruitment in the central nervous system during experimental bacterial meningitis.

Authors:  A Diab; H Abdalla; H L Li; F D Shi; J Zhu; B Höjberg; L Lindquist; B Wretlind; M Bakhiet; H Link
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

2.  Adherence of type I Streptococcus pneumoniae to tracheal epithelium of mice infected with influenza A/PR8 virus.

Authors:  M C Plotkowski; E Puchelle; G Beck; J Jacquot; C Hannoun
Journal:  Am Rev Respir Dis       Date:  1986-11

3.  Influenza A virus accelerates neutrophil apoptosis and markedly potentiates apoptotic effects of bacteria.

Authors:  M L Colamussi; M R White; E Crouch; K L Hartshorn
Journal:  Blood       Date:  1999-04-01       Impact factor: 22.113

4.  A randomized, double-blind, placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia. The International Acute Myeloid Leukemia Study Group.

Authors:  G Heil; D Hoelzer; M A Sanz; K Lechner; J A Liu Yin; G Papa; L Noens; J Szer; A Ganser; C O'Brien; J Matcham; A Barge
Journal:  Blood       Date:  1997-12-15       Impact factor: 22.113

5.  The M1 and M2 proteins of influenza A virus are important determinants in filamentous particle formation.

Authors:  P C Roberts; R A Lamb; R W Compans
Journal:  Virology       Date:  1998-01-05       Impact factor: 3.616

6.  Establishment of a Streptococcus pneumoniae nasopharyngeal colonization model in adult mice.

Authors:  H Y Wu; A Virolainen; B Mathews; J King; M W Russell; D E Briles
Journal:  Microb Pathog       Date:  1997-09       Impact factor: 3.738

7.  Pulmonary antibacterial defenses during mild and severe influenza virus infection.

Authors:  C L Nickerson; G J Jakab
Journal:  Infect Immun       Date:  1990-09       Impact factor: 3.441

8.  A randomized controlled phase III trial of recombinant human granulocyte colony-stimulating factor (filgrastim) for treatment of severe chronic neutropenia.

Authors:  D C Dale; M A Bonilla; M W Davis; A M Nakanishi; W P Hammond; J Kurtzberg; W Wang; A Jakubowski; E Winton; P Lalezari
Journal:  Blood       Date:  1993-05-15       Impact factor: 22.113

Review 9.  Pneumococcal diversity: considerations for new vaccine strategies with emphasis on pneumococcal surface protein A (PspA).

Authors:  D E Briles; R C Tart; E Swiatlo; J P Dillard; P Smith; K A Benton; B A Ralph; A Brooks-Walter; M J Crain; S K Hollingshead; L S McDaniel
Journal:  Clin Microbiol Rev       Date:  1998-10       Impact factor: 26.132

10.  Influenza type A virus-mediated adherence of type 1a group B streptococci to mouse tracheal tissue in vivo.

Authors:  W T Jones; J H Menna
Journal:  Infect Immun       Date:  1982-11       Impact factor: 3.441

View more
  23 in total

Review 1.  Postinfluenza bacterial pneumonia: host defenses gone awry.

Authors:  Megan N Ballinger; Theodore J Standiford
Journal:  J Interferon Cytokine Res       Date:  2010-09       Impact factor: 2.607

2.  Galectins regulate the inflammatory response in airway epithelial cells exposed to microbial neuraminidase by modulating the expression of SOCS1 and RIG1.

Authors:  Mihai Nita-Lazar; Aditi Banerjee; Chiguang Feng; Gerardo R Vasta
Journal:  Mol Immunol       Date:  2015-09-06       Impact factor: 4.407

3.  Direct interactions with influenza promote bacterial adherence during respiratory infections.

Authors:  Hannah M Rowe; Victoria A Meliopoulos; Amy Iverson; Perrine Bomme; Stacey Schultz-Cherry; Jason W Rosch
Journal:  Nat Microbiol       Date:  2019-05-20       Impact factor: 17.745

Review 4.  The inflammatory response triggered by Influenza virus: a two edged sword.

Authors:  Luciana P Tavares; Mauro M Teixeira; Cristiana C Garcia
Journal:  Inflamm Res       Date:  2016-10-15       Impact factor: 4.575

5.  Inactivated and live, attenuated influenza vaccines protect mice against influenza: Streptococcus pyogenes super-infections.

Authors:  Michael S Chaussee; Heather R Sandbulte; Margaret J Schuneman; Frank P Depaula; Leslie A Addengast; Evelyn H Schlenker; Victor C Huber
Journal:  Vaccine       Date:  2011-04-08       Impact factor: 3.641

6.  Innate immunity to influenza virus: implications for future therapy.

Authors:  Mitchell R White; Mona Doss; Patrick Boland; Tesfaldet Tecle; Kevan L Hartshorn
Journal:  Expert Rev Clin Immunol       Date:  2008-07-01       Impact factor: 4.473

7.  Infection with human metapneumovirus predisposes mice to severe pneumococcal pneumonia.

Authors:  Irena Kukavica-Ibrulj; Marie-Eve Hamelin; Gregory A Prince; Constance Gagnon; Yves Bergeron; Michel G Bergeron; Guy Boivin
Journal:  J Virol       Date:  2008-11-19       Impact factor: 5.103

8.  A mouse model of lethal synergism between influenza virus and Haemophilus influenzae.

Authors:  Lian Ni Lee; Peter Dias; Dongun Han; Sorah Yoon; Ashley Shea; Vladislav Zakharov; David Parham; Sally R Sarawar
Journal:  Am J Pathol       Date:  2009-12-30       Impact factor: 4.307

Review 9.  Otitis media among high-risk populations: can probiotics inhibit Streptococcus pneumoniae colonisation and the risk of disease?

Authors:  M John; E M Dunne; P V Licciardi; C Satzke; O Wijburg; R M Robins-Browne; S O'Leary
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-03-20       Impact factor: 3.267

Review 10.  Animal models for the study of influenza pathogenesis and therapy.

Authors:  Dale L Barnard
Journal:  Antiviral Res       Date:  2009-01-25       Impact factor: 5.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.